These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20238427)

  • 1. Characterization and classification of adverse drug interactions.
    Takarabe M; Shigemizu D; Kotera M; Goto S; Kanehisa M
    Genome Inform; 2010 Jan; 22():167-75. PubMed ID: 20238427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network analysis of adverse drug interactions.
    Takarabe M; Okuda S; Itoh M; Tokimatsu T; Goto S; Kanehisa M
    Genome Inform; 2008; 20():252-9. PubMed ID: 19425139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network-based analysis and characterization of adverse drug-drug interactions.
    Takarabe M; Shigemizu D; Kotera M; Goto S; Kanehisa M
    J Chem Inf Model; 2011 Nov; 51(11):2977-85. PubMed ID: 21942936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged.
    Wehling M
    J Am Geriatr Soc; 2009 Mar; 57(3):560-1. PubMed ID: 19278399
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug interactions and adverse events induced by drugs used in an intensive care unit].
    Plaza J; Alamo M; Torres P; Fuentes A; López F
    Rev Med Chil; 2010 Apr; 138(4):452-60. PubMed ID: 20668793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence.
    Matthews EJ; Frid AA
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):247-75. PubMed ID: 19932726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities.
    Frid AA; Matthews EJ
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):276-89. PubMed ID: 19941924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional classification of drugs by properties of their pairwise interactions.
    Yeh P; Tschumi AI; Kishony R
    Nat Genet; 2006 Apr; 38(4):489-94. PubMed ID: 16550172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in new drug interactions for pharmaceutical products in Japan.
    Yoshida N; Yamada A; Mimura Y; Kawakami J; Adachi I
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):421-7. PubMed ID: 16331581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A basic conceptual and practical overview of interactions with highly prescribed drugs.
    Dresser GK; Bailey DG
    Can J Clin Pharmacol; 2002; 9(4):191-8. PubMed ID: 12584577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse drug reactions to antibiotics and major antibiotic drug interactions.
    Novotný J; Novotný M
    Gen Physiol Biophys; 1999 Oct; 18 Spec No():126-39. PubMed ID: 10703731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of adverse drug reactions using drug and drug target interactions and graph-based methods.
    Lin SF; Xiao KT; Huang YT; Chiu CC; Soo VW
    Artif Intell Med; 2010; 48(2-3):161-6. PubMed ID: 19962282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of package inserts of potentially toxic drugs.
    Rodríguez-Sasiaín JM; Erill S
    Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):376-9. PubMed ID: 7118324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Improvement of package insert CYP information for prescription drugs marketed in Japan].
    Hirata-Koizumi M; Saito M; Urano T; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):12-8. PubMed ID: 16541745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug interactions clinically important for the dermatologist.
    Andersen WK; Feingold DS
    Arch Dermatol; 1995 Apr; 131(4):468-73. PubMed ID: 7726592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug interactions evaluation: an integrated part of risk assessment of therapeutics.
    Zhang L; Reynolds KS; Zhao P; Huang SM
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):134-45. PubMed ID: 20045016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avoiding drug interactions.
    Prescrire Int; 2004 Jun; 13(71):99-102. PubMed ID: 15233147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug interactions as a cause of drug side effects].
    Meier-Abt PJ; Meier C
    Ther Umsch; 1993 Jan; 50(1):42-8. PubMed ID: 8378866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anatomic-therapeutic-chemical classification of drugs].
    Skrbo A; Zulić I; Hadzić S; Gaon ID
    Med Arh; 1999; 53(3 Suppl 3):57-60. PubMed ID: 10870628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.